Kaya Holdings, Inc. Files 2023 Annual Report on Form 10-K

TL;DR

<b>Kaya Holdings, Inc. has filed its 2023 10-K report detailing its financial performance and corporate history.</b>

AI Summary

Kaya Holdings, Inc. (KAYS) filed a Annual Report (10-K) with the SEC on April 16, 2024. Kaya Holdings, Inc. filed its annual report on Form 10-K for the fiscal year ended December 31, 2023. The filing covers the period from January 1, 2023, to December 31, 2023. The company was formerly known as Alternative Fuels Americas, Inc. and Alternative Fuels America, Inc. Kaya Holdings, Inc. is classified under the Pharmaceutical Preparations industry (SIC 2834). The filing includes detailed financial data for the fiscal years 2021, 2022, and 2023.

Why It Matters

For investors and stakeholders tracking Kaya Holdings, Inc., this filing contains several important signals. This 10-K filing provides a comprehensive overview of Kaya Holdings' financial health and operational status for the fiscal year 2023, crucial for investors assessing the company's performance and future prospects. The historical company name changes indicate potential strategic shifts or rebranding efforts, which may be relevant for understanding the company's evolution and market positioning.

Risk Assessment

Risk Level: medium — Kaya Holdings, Inc. shows moderate risk based on this filing. The filing is a standard 10-K, which is a comprehensive annual report. However, without specific financial performance data (revenue, net income, etc.) or risk factor details within the provided text, a definitive risk assessment is limited to 'medium' based on the nature of annual filings for public companies.

Analyst Insight

Investors should review the full 10-K filing to understand Kaya Holdings' financial performance, strategic direction, and associated risks for the fiscal year 2023.

Key Numbers

• 2023-12-31 — Fiscal Year End (Reporting period)
• 2024-04-16 — Filing Date (Date of submission)
• 2023 — Fiscal Year (Primary reporting year)
• 2022 — Previous Fiscal Year (Comparative year)
• 2021 — Prior Fiscal Year (Comparative year)

Key Players & Entities

• Kaya Holdings, Inc. (company) — Filer name
• Alternative Fuels Americas, Inc. (company) — Former company name
• Alternative Fuels America, Inc. (company) — Former company name
• 2023-12-31 (date) — Fiscal year end
• 2024-04-16 (date) — Filing date
• Fort Lauderdale, FL (location) — Business address

FAQ

Industry Context

Kaya Holdings, Inc. operates within the Pharmaceutical Preparations industry, as indicated by its SIC code 2834. This sector involves the manufacturing of drugs and medicines.

Regulatory Implications

As a publicly traded company, Kaya Holdings, Inc. is subject to the reporting requirements of the Securities and Exchange Commission (SEC), including the annual filing of Form 10-K.

What Investors Should Do

1. Review the full 10-K filing for detailed financial statements and management discussion.
2. Analyze the company's historical name changes for insights into strategic evolution.
3. Assess the company's position within the Pharmaceutical Preparations industry.

Key Dates

• 2023-12-31: Fiscal Year End — End of the reporting period for the 10-K.
• 2024-04-16: Filing Date — Date Kaya Holdings, Inc. submitted its 10-K filing.

Year-Over-Year Comparison

This is the initial 10-K filing for Kaya Holdings, Inc. for the fiscal year 2023. Previous filings were under former company names.

Key Financial Figures

• $0.07 — ed on the closing price on such date of $0.07 of the Company's common stock on the OT
• $300 — tial prices for one facility range from $300 for a group microdose session to $3,500
• $3,500 — m $300 for a group microdose session to $3,500 for an individual high-dose session, wi
• $15,000 — cing first-time full dose treatments at $15,000 (these prices do not include the cost o
• $500 — psilocybin, which can run from $300 to $500). 3 KAYS expects its facility to off
• $700,000 — skyline from our 7 th floor facility. $700,000+ Institutional Investment in Fifth Dime
• $350,000 — On June 12, 2023 the Company received $350,000 as a first installment for a working ca
• $150,000 — ompany received a second installment of $150,000 on the same terms, bringing the total w
• $500,000 — nging the total working capital loan to $500,000. In consideration for CVC extending th
• $61,200.00 — January 23, 2024, the Company received $61,200.00 and on March 12, 2024,the Company recei
• $510,000 — on that it had previously purchased for $510,000 as part of our focus on moving our cann
• $769,500 — as. We sold the Property for a price of $769,500, less commissions and customary closing
• $302,000 — realized net proceeds of approximately $302,000. On April 21, 2023 the Company conclud
• $210,000 — m Retail Cannabis Store ("Store 2") for $210,000, less a 6% closing commission and minor
• $75,000 — penses. After these expenses and paying $75,000 to resolve three non-performing store l

Filing Documents

• kays_10k.htm (10-K) — 1376KB
• ex31_1.htm (EX-31.1) — 18KB
• ex32_1.htm (EX-32.1) — 8KB
• image_001.jpg (GRAPHIC) — 5KB
• image_002.jpg (GRAPHIC) — 17KB
• image_003.jpg (GRAPHIC) — 5KB
• image_004.jpg (GRAPHIC) — 17KB
• image_001a.jpg (GRAPHIC) — 62KB
• image_002a.jpg (GRAPHIC) — 13KB
• image_003a.jpg (GRAPHIC) — 4KB
• image_004a.jpg (GRAPHIC) — 40KB
• image_005a.jpg (GRAPHIC) — 36KB
• kays_1.jpg (GRAPHIC) — 8KB
• 0001903596-24-000238.txt (&nbsp;) — 6362KB
• kays-20231231.xsd (EX-101.SCH) — 53KB
• kays-20231231_cal.xml (EX-101.CAL) — 57KB
• kays-20231231_def.xml (EX-101.DEF) — 96KB
• kays-20231231_lab.xml (EX-101.LAB) — 281KB
• kays-20231231_pre.xml (EX-101.PRE) — 214KB
• kays_10k_htm.xml (XML) — 1039KB

Signatures

Signatures 34 CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS Information contained in this Annual Report contains " forward-looking statements " within the meaning of Section 27A of the Securities Act of 1933, as amended (the " Securities Act ") and Section 21E of the Securities Exchange Act of 1934, as amended (the Exchange Act "). These forward-looking statements are contained principally in the sections titled "Item 1. Business," "Item 1A. Risk Factors," and "Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations " and are generally identifiable by use of the words " may ," " will ," " should ," " expect ," " anticipate ," " estimate ," " believe ," " intend " or " project " or the negative of these words or other variations on these words or comparable terminology. The forward-looking statements herein represent our expectations, beliefs, plans, intentions or strategies concerning future events. Our forward-looking statements are based on assumptions that may be incorrect, and there can be no assurance that any projections or other expectations included in any forward-looking statements will come to pass. Moreover, our forward-looking statements are subject to various known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from future results, performance or achievements expressed or implied by any forward-looking statements. Except as required by applicable laws, we undertake no obligation to update publicly any forward-looking statements for any reason, even if new information becomes available or other events occur in the future. Available Information We file annual, quarterly and special reports and other information with the Securities and Exchange Commission ("SEC") that can be obtained from the SEC by telephoning 1-800-SEC-0330. The Company's filings are also available through the SEC's Electronic Data Gath

View Full Filing

View this 10-K filing on SEC EDGAR